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Abstract: As considerable inter-species differences exist in xenobiotic metabolism, developing new 
pharmaceutical therapies for use in different species is fraught with difficulties. For this reason, very few 
medicines have been registered for use in rabbits, despite their importance in inter alia meat and fur 
production. We have developed a rapid and sensitive screening system for drug safety in rabbits based on 
cytochrome P450 enzyme assays, specifically CYP1A1, CYP1A2 and CYP3A6, employing an adaptation 
of the luciferin-based clinical assay currently used in human drug screening. Short-term (4-h) cultured 
rabbit primary hepatocytes were treated with a cytochrome inducer (phenobarbital) and 2 inhibitors (alpha-
naphthoflavone and ketoconazole). In parallel, and to provide verification, New Zealand white rabbits were 
dosed with 80 mg/kg phenobarbital or 40 mg/kg ketoconazole for 3 d. Ketoconazole significantly increased 
CYP3A6 gene expression and decreased CYP3A6 activity both in vitro and in vivo. CYP1A1 activity was 
decreased by ketoconazole in vitro and increased in vivo. This is the first report of the inducer effect of 
ketoconazole on rabbit cytochrome isoenzymes in vivo. Our data support the use of a luciferin-based assay 
in short-term primary hepatocytes as an appropriate tool for xenobiotic metabolism assays and short-term 
toxicity testing in rabbits.
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INTRODUCTION
Rabbits are livestock animals in increasing demand for meat and fur production, widely used as laboratory models and 
a popular pet species. Despite this, only very few medicines have been registered for rabbits. Veterinary practitioners 
are frequently forced to use medicines registered for dogs or cats, and the high incidence of resulting iatrogenic 
illness reflects the differences in drug metabolising capacity between species. The investigation of drug metabolism 
in this species is timely.
Despite the highly conserved functions of cytochrome P450 enzymes, significant inter-species variance exists in 
the activity and substrate-specificity of individual enzymes. The cytochrome P450 (CYP450) system plays a key role 
in xenobiotic metabolism, where the CYP enzymes catalyse Phase I reactions. In humans, CYP1A1 is involved in 
the biotransformation of polycyclic aromatic hydrocarbons, CYP1A2 metabolises phenacetin, theophylline, caffeine, 
imipramine and propranolol, and CYP3A is the most abundant CYP isoenzyme, metabolising over half of current drugs 
(Boek-Dohalská et al., 2001). 
Valuable information about the safety of drugs, feed additives and other substances can be obtained by measuring 
their impact on CYP enzyme activities. Animal models are the gold standard but ethical and cost considerations favour 
in vitro systems such as primary hepatocyte cell cultures, which closely approximate to parent cells and provide high 
initial CYP450 activity (Guillouzo, 1998). A highly sensitive luminescence assay has been developed for assaying the 
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human cytochrome system (Cali et al., 2006), and is specific for CYP isoenzyme activity. We tested the luminescent 
assay’s applicability for rabbit CYP detection in rabbit hepatocytes, assuming functional similarity between rabbit 
CYP3A6 and human CYP3A4, as the 2 enzymes are highly similar (Franklin, 1995). We also measured changes in 
CYP1A1, CYP1A2 and CYP3A6 gene expression levels, in vivo and in vitro. 
MATERIALS AND METHODS
Bioluminescence assay: The luminogenic compounds are beetle luciferin derivatives that are converted by CYP 
enzymes to luciferin. D-luciferin is formed and detected in a second reaction with the Luciferin Detection Reagent, 
generating luminescence proportional to CYP activity.
Xenobiotics: Our study utilised phenobarbital and ketoconazole, which are characteristic inducer and inhibitor agents 
of CYP450 enzymes.
Rabbit hepatocyte isolation and plating
Livers were obtained from female, 6-wk-old New Zealand white rabbits weighing approximately 1.5 kg. The animals 
were housed in stainless steel cages, 2 rabbits per cage, provided food and water ad libitum for 1 wk before use. 
Rabbits were anesthetised by the combination of xylazine (5 mg/kg body weight (BW), 2% solution) and ketamine 
(60 mg/kg BW, 10% solution) administered intramuscularly. After aseptic opening of the abdominal cavity, the portal 
vein of the liver was cannulated and rabbit liver was perfused with calcium-free Hank’s buffer containing 0.5 mM 
egtazic acid (EGTA) for 10 min at a rate of 30 mL/min. The liver was then removed from the abdominal cavity and 
perfused with Hank’s buffer containing 2.5 mM calcium-chloride and 2.5 mM magnesium-chloride and collagenase 
type IV (0.5 mg/mL) for 25 min at a flow rate of 30 mL/min. All perfusion buffers were preheated to 37°C and 
equilibrated with 95% O2 / 5% CO2 before use. 
The next steps were performed under laminar flow. The liver was removed from the Glisson capsule and gently 
shaken in bovine serum albumin (BSA) buffer (25  mg/mL) to release the hepatocytes. The obtained suspension 
was filtered through a 125 µm pore size nylon mesh and then centrifuged at 105 g for 4 min., after which the cell 
pellet was re-suspended in Williams E medium (Sigma-Aldrich, St. Louis, USA) containing 2 mM glutamine and 
7.5% NaHCO3. The washing procedure was repeated twice. The plating medium was Williams E supplemented with 
5% fetal bovine serum (FBS), 5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenium, 5 ng/mL epidermal growth 
factor (EGF), 50 IU/mL penicillin, 50 µg/mL streptomycin and 1 µM dexamethasone. The viability of the hepatocytes 
as assessed by the Trypan blue exclusion test was 88%. Hepatocyte cells (106/0.5 mL/well) were added to 24-well 
polystyrene plates (Corning, New York, USA) coated with collagen type I (Sigma-Aldrich, St. Louis, USA). After 4 h of 
incubation at 37°C in 5% CO2 atmosphere the cells were attached to the surface (Figure 1).
Rabbit hepatocyte treatment
Four hours after isolation, the cells were washed twice with serum-free medium and treated either with inducer or with 
inhibitors for 2 h. Phenobarbital, ketoconazole and alpha-naphthoflavone were used as model compounds to induce 
stimulation or inhibition of the CYP enzymes. For general CYP450 enzyme stimulation we used 500 µM phenobarbital, 
for CYP1A2 inhibition 50 µM alpha-naphthoflavone and for CYP1A1 and CYP3A6 inhibition 25 µM ketoconazole. The 
inhibitor compounds were added to the cell cultures separately. After treatment, the cells were washed twice in PBS 
and the P450-Glo™ assays (Luciferin-CEE, Luciferin-1A2, Luciferin-IPA, Luciferin-PFBE; Promega, Madison, USA) 
were then performed according to the manufacturer’s recommendations; the luminogenic substrates were added 
to each well, respectively. After the required time, the Luciferin Detection Reagents (Promega, Madison, USA) were 
added to the cells and the luminescence was detected by a luminometer (Victor X2, PerkinElmer, Massachusetts, 
USA). Hepatocyte cells were collected in Tergitol buffer for protein determination (Bicinchoninic Acid Protein Assay Kit, 
Thermo Scientific, Rockford, USA).
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Quantitative Real-Time PCR
After treatment, culture medium containing the treatment compounds was removed and changed to serum-free 
culture medium. Five hours after treatment, 1 mL of ice-cold RNAzol RT reagent (Sigma-Aldrich) was added to the 
hepatocyte culture and the samples collected and kept at –80°C until further processing. Total RNA was isolated 
from the cells according to the manufacturer’s instructions. Quantity, A260/A280 and A260/A230 ratios of the 
extracted RNA were determined using a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, 
USA). Synthesis of the first strand of cDNA from 1000 ng of total RNA was achieved using RevertAid H Minus First 
Strand cDNA Synthesis Kit (Fermentas, St. Leon-Roth, Germany) according to the manufacturer’s recommendations, 
using the random hexamer as a priming method. Quantitative real-time polymerase chain reaction (qRT-PCR) was 
Figure 1: Rabbit primary hepatocyte cell culture after 4 h incubation. Phase-contrast micrograph, magnification: 
200×. Primary hepatocytes display the typical cubic cell shape and often contain 2 nuclei.
Table 1: Sequence of primer sets used for quantitative real-time PCR.
Gene symbol Accession number Primer sequences* Product size
(bp)
Efficiency R2
GAPDH NM_001082253 F 5’-GGCAAAGTGGATGTTGTCGC-3’
R 5’-GCCGTGGGTGGAATCATACT-3’
87 0.887 0.988
Beta-actin NM_001101683 F 5’-GTGCTTCTAGGCGGACTGTT-3’
R 5’-CGGCCACATTGCAGAACTTT-3’
240 0.766 0.986
HPRT1 NM_001105671 F 5’-AGCCCCAGCGTTGTGATTAG-3’
R 5’-TCGAGCAAGCCTTTCAGTCC-3’
141 0.905 0.982
CYP1A1 NM_001171072 F 5’-CTTCGGAGCTGGGTTTGACA-3’
R 5’-AGAGGTGTGTCGGAAGGTCT-3’
199 0.960 0.982
CYP1A2 NM_001171121 F 5’-GTGGCAAATCAACCACGACC-3’
R 5’-CGTGACCTTCTCACTCAGGG-3’
115 0.813 0.983
CYP3A6 NM_001171268 F 5’-CAAAAGCGCCGAGTGGATTT-3’
R 5’-AAGTCTGCCAGCAATTGGGT-3’
327 0.731 0.990
*All primers were designed using the Primer-BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast) (Ye et al., 2012).
HPRT1: hypoxanthine phosphoribosyl transferase-1, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, F: forward; R: reverse.
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performed using the iQ SYBR Green Supermix kit (BioRad, Hercules, CA, USA) on the MiniOpticon System (BioRad). 
The cDNA was diluted 5-fold, before equal amounts were added to duplicate qRT-PCR reactions. The tested 
genes were CYP1A1, CYP1A2 and CYP3A6. Hypoxanthine phosphoribosyl transferase-1 (HPRT1), glyceraldehyde-
3-phophate dehydrogenase (GAPDH) and beta-actin were used as reference genes. Primer sequences are listed in 
Table 1. For each PCR reaction, 2.5 µL cDNA was added directly to a PCR reaction mixture, set to a final volume of 
25 µL, containing 1× concentrated iQ SYBR Green Supermix and 0.2 µM of the appropriate primers. The thermal 
profile for all reactions was 3 min at 95°C, then 40 cycles of 20 s at 95°C, 30 s at 60°C, and 30 s at 72°C. At the 
end of each cycle, fluorescence monitoring was set for 10 s.
Rabbits, housing and treatments
Twelve clinically healthy New Zealand White rabbits (S & K Lap Nyúltenyésztő Kft., Kartal, Hungary) 6 wk old were 
used in this study. The animals were housed in stainless steel cages (40×60×80 cm), 2 rabbits per cage, at the 
animal housing facility of the Department of Pharmacology and Toxicology, acclimated at 20±2°C on a 12 h light 
12 h dark schedule. One hundred grams of commercial pellet feed was provided daily and water was available 
ad libitum. The rabbits (mean weight 1350±96 g) were randomly divided into 3 groups comprising a control group, 
a phenobarbital group (80 mg/kg BW) and a ketoconazole group (40 mg/kg BW). The xenobiotics were administered 
to the rabbits for 3 consecutive days, per os. On the third day, the rabbits were anesthetised by a combination of 
Zoletil® injection (0.3 mL/kg BW) and Xylavet injection (0.25 mL/kg BW) intramuscularly. After aseptic opening of 
the abdominal cavity, the portal vein of the liver was cannulated; the liver was perfused with neutral buffered saline 
and then removed, flash-frozen in liquid nitrogen and stored at –80°C till further processing.
Microsome separation
The livers were homogenised with 2 volumes of ice-cold buffer (1.15% KCl, 0.1  mM EDTA, pH 7.4) by a 
Potter-Elvehjem homogeniser. Microsomes were isolated by differential ultracentrifugation (Beckman L7-
65 Ultracentrifuge, Beckman-Coulter) according to (Nebbia et al., 2001). Protein concentrations were measured 
by the BCA protein assay kit.
Statistical analyses
Relative gene expression levels of the gene of interests were calculated by the Relative Expression Software 
Tool (REST) 2009 Software. Statistical analyses were performed by Statistica 12 software (Statsoft, Tulsa, USA). 
Differences between means were evaluated by one-way analysis of variance (ANOVA) followed by a post hoc 
comparison using Fisher’s least significant difference (LSD) test.
Ethics statement
The animal trials were conducted according to approved laboratory animal experimentation ethics under national 
and European law, compatible with the conditions set out in the Guidelines for Ethical Conduct in the Care and 
Use of Nonhuman Animals in Research. Rabbits were anesthetised by the combination of xylazine (5 mg/kg BW, 
2% solution) and ketamine (60 mg/kg BW, 10% solution) intramuscularly. The study was authorised by the Local 
Institutional Animal Care Committee (LIACC) of the Faculty of Veterinary Science (Permit number: 3/2015).
RESULTS
Results of the in vitro experiments
The rabbit primary hepatocyte cell culture protein concentration was effectively standardised (800±30  µg/
mL) in each well. By exclusion, any differences in CYP activity were therefore caused by induction or inhibition. 
Phenobarbital at 500 µM was an effective inducer of all 3 tested isoenzymes. Alpha-naphthoflavone at 50 µM 
had no effect on any of the 3 examined isoenzymes. Ketoconazole at 25 µM significantly inhibited CYP1A1 and 
CYP3A6. 
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In respect to CYP1A1, ketoconazole-evoked inhibition was so powerful that CYP1A1 activity was almost totally 
suppressed (Figure 2A). The alpha-naphthoflavone did not cause inhibition on the activity of CYP1A2  enzyme 
(P=0.069) (Figure 2B). Regarding CYP3A6, both induction and ketoconazole-mediated inhibition were highly 
effective (Figure 2C).
Luciferin-IPA substrate was used to measure 
CYP3A6  activity, as Luciferin-PFBE did not generate 
sufficient luminescent signal. The obtained Relative 
luminescence unit (RLU) was 261±26  for the control 
cells, 312±77 for the induced cells and 212±15 for the 
inhibited cells. This substrate did not work well with the 
rabbit CYP3A6 enzyme. 
Gene expression
PCR results are shown in Figure 3. Phenobarbital 
treatment upregulated the CYP3A6  gene, while 
expression of CYP1A1  and CYP1A2  remained 
unchanged. CYP1A1  and CYP3A6  genes were 
upregulated after treatment with ketoconazole.
Results of the in vivo experiments
Protein concentrations of the microsomes from 
the different groups of animals were similar 
(23335±2344  µg/mL) in each sample. Microsomes 
from the phenobarbital treated rabbits showed increased 
activity of all 3 isoenzymes (CYP1A1, CYP1A2, CYP3A6) 
(Figure  4). Ketoconazole treatment did increase the 
activity of CYP1A1, decreased the activity of CYP3A6, 



















































































Figure 2: Changes in cytochrome enzyme activity 
in rabbit primary cell cultures. Control: non-treated, 
PB:  treated with 500  µM phenobarbital for 2  h, 
ANF: treated with 50 µM alpha-naphthoflavone for 2 h, 
KTZ:  treated with 25 µM ketoconazole for 2 h. (n=4/
group; *P<0.05; **P<0.01; ***P<0.001) Data are 
shown as mean±standard error. (A) CYP1A1  activity. 


























Figure 3: Relative gene expression of the CYP genes 
in rabbit primary cell cultures.  PB: phenobarbital, 
500 µM;  KTZ: ketoconazole, 25 µM;  ANF: alpha-
naphthoflavone, 50 µM. The cell cultures were treated 
for 2 h. (n=4/group; *P<0.01, ***P<0.001) Data are 
shown as mean±standard error.
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PCR results are shown in Figure 5. After 3  d of 
phenobarbital treatment, gene expression levels were 
increased for all 3 isoenzymes. Ketoconazole treatment 
did not alter the expression of CYP1A1 and CYP1A2, 
but increased expression of the CYP3A6.
DISCUSSION
Rabbits provide an excellent model for investigating 
the CYP450 system, as they have high initial enzyme 
activity compared to other lab species such as 
rodents (Nebbia et  al., 2003; Fink-Gremmels, 2008). 
Primary hepatocyte cell cultures are a suitable tool for 
assaying enzyme induction and inhibition, and the rapid 
degradation of CYP enzymes in culture (Paine, 1996; 
Eeckhoutte et al., 2002) can be obviated by using 4-h 
cultures (Beigel et al., 2008; Noel et al., 2013).
Phenobarbital-mediated induction is regulated 
at the transcriptional level (Moore et  al., 2002), 
while ketoconazole (Ekroos and Sjögren, 2006) 
and α-naphthoflavone (Cho et  al., 2003) cause 
conformational changes in the enzyme structure by 
binding to the enzyme’s active site. Our results showed that ketoconazole acts as an inducer at the transcriptional 
level in rabbit CYP1A1 and CYP3A6, in vitro. Our findings are in accordance with Korashy et al. (Korashy et al., 2007) 
where ketoconazole was found to induce CYP1A1 at the transcriptional and protein level in human and murine cell 
lines. Others have found that ketoconazole is an effective CYP1A1 inhibitor in humans (Paine et al., 1999) and rats 
(Elsherbiny et al., 2008); our experiments are concordant, showing that ketoconazole is also a highly effective inhibitor 
of rabbit CYP1A1, in vitro. In our study, ketoconazole had opposite effects at the transcriptional and protein levels 
on CYP450 enzymes, in vitro. In vivo, however, ketoconazole increased CYP1A1 activity. According to the qRT-PCR 

















































































Figure 4: Changes in cytochrome enzyme activity in 
rabbit microsomes. Control:  non-treated, PB:  treated 
with 80 mg kg body weight (BW) phenobarbital for 3 d, 
KTZ: treated with 40 mg/kg BW ketoconazole for 3 d. 
(n=4/group; *P<0.05; **P<0.01; ***P<0.001) Data are 



























Figure 5: Relative gene expression of the CYP genes 
in rabbits.  PB:  phenobarbital, 80  mg/kg  body 
weight (BW),  KTZ:  ketoconazole, 40  mg/kg  BW. 
The rabbits were treated orally for 3  d. (n=4/group; 
*P<0.05; **P<0.01; ***P<0.001) Data are shown as 
mean±standard error.
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in vitro, but the gene expression level of CYP1A1 remained unchanged in vivo after 3 d of ketoconazole treatment. 
Ketoconazole upregulated the gene expression of CYP3A6 both in vitro and in vivo, in line with previous findings that 
ketoconazole increased the gene expression of CYP3A4 in human cell lines and human primary hepatocytes (Novotna 
et al., 2014). This is the first proof of the inducer effect of ketoconazole on CYP1A1 enzyme activity in vivo in rabbits.
The inducer effect of phenobarbital was most pronounced in the CYP3A6  enzyme in vitro, and is in line with 
phenobarbital’s known stimulating effect on the CYP3A subfamily (Ohno et al., 2009). Phenobarbital treatment caused 
increased gene expression and increased CYP enzyme activity in all examined isoenzymes both in vitro and in vivo. 
Luciferin-IPA is the most sensitive substrate for CYP3A4  (Cali, Ma et al., 2006). This substrate worked well with 
the rabbit CYP3A6  enzyme, providing further evidence of the functional similarity of the 2 enzymes. The RLU 
values obtained for all 3 CYP activities in rabbit hepatocytes are very comparable with RLU values found in human 
hepatocytes HepG2 (Yueh et al., 2005) and HepaRG (Mueller et al., 2014), and in freshly isolated and cryoplateable 
hepatocytes (Moeller et al., 2011). The Luciferin-PFBE substrate did not produce detectable signal with the rabbit 
CYP3A6 enzyme. Others have used the HepG2 human hepatoma cell line with the same cell numbers as used in 
our study and found RLU of approximately 1000 in 2D cell cultures (Lan et al., 2010). In another study, recombinant 
(yeast) CYP3A4  at a concentration of 5×107  cells/mL in 200  µL medium was used, producing an RLU value of 
approximately 300 (Neunzig et al., 2011). According to these and our studies, the Luciferin-PFBE substrate did not 
produce a strong luminescent signal with either human CYP3A4 or rabbit CYP3A6.
Compared to other cytochrome assays, the P450-GloTM Assays have key advantages. For example, the Masters 
method (Masters et al., 1967) is not specific for individual isoenzymes and can only provide indirect measurement 
of overall cytochrome activity. While the similarly indirect Nash method (Nash, 1953) does provide information 
regarding specific CYP isoenzymes, it is insufficiently sensitive to register most xenobiotic-induced changes. Indirect 
but isoenzyme-specific measurement is possible with high-performance liquid chromatography (Lahoz et al., 2008; 
Lee et al., 2013) and Western blot (LeCluyse, 2001), but these methods are complex and problematic because the 
amount of CYP protein is not directly proportional to CYP activity. Analytical methods based on 3H- or 14C-labeled 
drug substrates are accurate but require protective equipment, subsequent decontamination and specialised waste 
disposal (Zlokarnik et al., 2005). The fluorescence methods suffer from optical interference between test substances 
and CYP substrates (Cali, Ma et al., 2006). In contrast to these, the P450-GloTM CYP assay provides a simple and 
specific method for the detection of cytochrome activity.
In conclusion, the cytochrome P450  luminescent method is a fast, safe, simple and sensitive tool for testing the 
effect of active substances on the rabbit’s cytochrome P450 system. Our in vitro findings were largely consistent 
with the in vivo results, validating the short-term primary hepatocyte cell culture method in xenobiotic metabolism 
investigations and in short-term toxicity screening. This therefore appears to be an effective and cost-effective way to 
progress much-needed new medicines to registration in rabbits.
Furthermore, the changes in rabbit CYP1A1 and CYP3A6 enzymes after phenobarbital and ketoconazole exposure ran 
in parallel with those previously described for human CYP1A1 and CYP3A4 enzymes. These results suggest that the 
rabbit is a good model for preliminary pharmacological investigations. 
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